Chemotherapy News and Research

Latest Chemotherapy News and Research

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.

20 Aug 2010

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Radioactive yttrium-90 labelled resin microspheres (SIR-Spheres; Sirtex Medical, Sydney, Australia) appear to be a safe and effective treatment for patients with colorectal cancer liver metastases who have failed available chemotherapy options, according to the final results of a prospective clinical multi-centre phase II trial conducted by the Italian Society of Locoregional Therapies in Oncology (SITILO) and published in the British Journal of Cancer.

20 Aug 2010

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.

19 Aug 2010

Bridge for cross-cultural cancer education

Most cancers are easier to treat if detected early, so cancer educators emphasize the benefits of screening and prompt treatment. But for immigrants and other "medically underserved communities," simply handing out a brochure on early detection — even if it's been translated into the appropriate language — may not work.

19 Aug 2010

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Although hematopoietic cell transplantation (HCT) cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure, according to a recent study published online in Blood, the journal of the American Society of Hematology.

19 Aug 2010

Scientists reveal lab approach method to treat neuroblastoma in children

A study led by scientists at The Hospital for Sick Children (SickKids) reveals a new method of identifying drugs to treat children suffering from fatal cancers for which an effective treatment has not been found. Rather than developing a new drug from scratch, which is a complicated and time-consuming process, they tried a different approach: in the lab, they tested existing drugs on cancer stem cells from young patients with neuroblastoma, one of the common cancers of infants and children.

19 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

ImmunoCellular Therapeutics today announced second quarter results for the period ended June 30, 2010. The Company utilized $1.13 million of cash in its operations during the quarter. The increase in net burn is reflective of increased personnel costs as well as increase in Research and Development costs associated with the planned phase II clinical trial for ICT-107.

18 Aug 2010

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

BAC BV, the leading provider of antibody-based affinity purification technology, today announced that it has entered into a licence agreement with Octapharma (Lachen, Switzerland), an independent, global provider of human proteins for life-threatening diseases.

17 Aug 2010

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

An experimental drug called olaparib has been shown to shrink tumours in women whose advanced cancers were caused by faults in their BRCA genes.

17 Aug 2010

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

A UCSF-led team has discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. Their finding also may explain, they say, why some other age-related hematological disorders develop.The study, reported in "Cell Stem Cell" and reviewed in Cell Stem Cell and Cell, opens a new frontier for studying the molecular underpinnings of adult leukemia.

17 Aug 2010

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

Beaver Medical Group is expanding the range of ophthalmological services offered at its Banning Specialty Care Center. By relocating the SCC ophthalmology services within the facility and purchasing new technology, patients will have greater access and more convenience when they need eye care.

17 Aug 2010

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.

17 Aug 2010

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

For the first time, Salt Inducible Kinase 2 (SIK2) has been found to play a critical role in cell division and to regulate the response of some ovarian cancers to chemotherapy.Findings were reported by researchers from The University of Texas MD Anderson Cancer Center in the August issue of Cancer Cell. The study adds to growing evidence that combination therapies targeting different phases of the cell division cycle are vital for optimal cancer treatment.

17 Aug 2010

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that the U.S. Food and Drug Administration (FDA) has provided the company 510(k) clearance to market the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures.

16 Aug 2010

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2010.“We are working expeditiously to complete the work needed to prepare for a meeting with the FDA. Once the necessary information is available, we will request an End of Review meeting to discuss the next steps for the APF530 New Drug Application.”

16 Aug 2010

Scientists identify genes associated with aggressive breast cancer

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment strategies for patients.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Childhood brain tumor survivors may be vulnerable to physical declines associated with aging: Study

A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.

16 Aug 2010

Fertility preservation may be unsafe for leukemia patients: Study

Although the use of ovarian tissue cryopreservation and transplantation has lead to 13 live births in women with lymphoma or solid tumors, this method of fertility preservation may be unsafe for patients with leukemia, according to a recent study published online in Blood, the journal of the American Society of Hematology.

16 Aug 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Trial shows positive results for radioembolisation technique for colorectal cancer liver metastases treatment

SIR-Spheres safe, effective for patients with colorectal cancer liver metastases who have failed chemotherapy

Advaxis completes low dose group patient dosing in phase II cervical dysplasia clinical trial study

Bridge for cross-cultural cancer education

Hematopoietic cell transplantation survivors report of chronic health condition after procedure

Scientists reveal lab approach method to treat neuroblastoma in children

FDA grants orphan drug designation to NephRx's lead product NX001

ImmunoCellular Therapeutics raises $6.5 million in second quarter 2010

BAC, Octapharma enter licence agreement for G-CSF CaptureSelect custom affinity ligand

Experimental drug benefits women with advanced ovarian or breast tumours caused by BRCA gene faults

Scientists identify possible therapeutic strategy for reducing leukemia risk from chemotherapy

Beaver Medical Group expands range of ophthalmological services at Banning Specialty Care Center

CEL-SCI Corporation third quarter 2010 net loss decreases to $0.6 million

SIK2 impacts cell division cycle, regulates ovarian cancer response to chemotherapy: Research

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

Scientists identify genes associated with aggressive breast cancer

New T cell engineering approach can improve success rate of immune-cell therapies

Childhood brain tumor survivors may be vulnerable to physical declines associated with aging: Study

Fertility preservation may be unsafe for leukemia patients: Study

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in